Patienter behandlet med IntronA og ribavirin kombinationsbehandling og zidovudin kan herudover have en øget risiko for at udvikle anæmi (lavt antal røde blodceller).
Additionally, patients treated with IntronA and ribavirin combination therapy and zidovudine could be at increased risk of developing anaemia (low number of red blood cells).